CyPath® Lung Identifies Stage 1A Lung Cancer in High-Risk Patient Despite Inconclusive Imaging
BioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW),a biotechnology company addressingthe need for noninvasive, accurate tests for the detection of early-stage cancer, today released a new case study of a complex clinical case in which CyPath® Lung identified Stage 1A adenocarcinoma lung cancer in…
KVC Health Systems and WellSky® Partner to Improve Behavioral Health Care
KVC Health Systems and WellSky® Partner to Improve Behavioral Health Care WellSky, a global health and community care technology and services company, today announced that KVC Health Systems, a national leader in mental health, child welfare, and health and human services…
Exact Sciences Secures Medicare Coverage for Oncodetect™ MRD Test in Colorectal Cancer
Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that its Oncodetect™ molecular residual disease (MRD) test has received Medicare coverage through the Centers for Medicare & Medicaid Services’ (CMS) Molecular Diagnostic Services…
First Patient Receives CorWave’s Innovative Undulating Membrane Heart Pump
CorWave, a medical device company, announces the world’s first implantation in a patient of its Left Ventricular Assist System (LVAS), the first heart pump based on breakthrough wave membrane technology. The procedure was performed by the team at St Vincent’s…
Aptar’s Material Science Innovation Enhances Moisture and Oxygen Control for Drugs and Devices
A global leader in drug and consumer product dosing, dispensing and protection technologies, today announced that it has developed a dual-active material science technology engineered to simultaneously control moisture and oxygen. This technology is designed to provide a singular solution…
Petspan Unveils First Telemedicine Protocol with Rapamycin for Treating Feline Hypertrophic Cardiomyopathy
Petspan, the veterinary telemedicine division of longevity health company Healthspan, today announced the launch of the industry’s first remote-care protocol delivering rapamycin therapy to cats diagnosed with hypertrophic cardiomyopathy (HCM). Our HCM protocol gives cat parents access to a therapy supported by…
OhioGuidestone Scales Use of Greenspace Health’s Platform to Improve Mental Health Care
OhioGuidestone, Ohio’s leader in community behavioral healthcare, announced today the expansion of its partnership with Greenspace Health, extending the use of its Measurement-Based Care (MBC) technology across the organization’s behavioral health services to further improve their quality of care, client outcomes…
Cardio Diagnostics and AGEPHA Pharma Collaborate to Enhance Precision Care for Coronary Inflammation
A precision cardiovascular medicine company with a pioneering technology at the intersection of epigenetics and AI, today announced an agreement with AGEPHA Pharma that will enable the validation of a precision-guided approach to treating inflammation-driven coronary heart disease (CHD). Specifically, AGEPHA Pharma…
Tempus Extends AI-Powered Care Pathway Platform to Breast Cancer
A technology company leading the adoption of AI to advance precision medicine and patient care, today announced the expansion of its care pathway intelligence platform, Tempus Next, into breast cancer. Since its launch in 2024, Tempus Next has screened thousands of…
ImmunoPrecise Antibodies Names Jon Lieber to Board of Directors
ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“IPA” or the “Company”), an AI-powered biotherapeutics company, today announced the appointment of Jon Lieber to its Board of Directors, effective immediately. Mr. Lieber has over 30 years of financial and strategic leadership experience in…
AI Platform Evidently Announces Partnership With Allina Health
AI Platform Evidently Announces Partnership With Allina Health Clinical data intelligence platform Evidently is announcing an extended partnership with Allina Health, under which Evidently’s AI system will process millions of patient encounters each year to reduce clinicians’ cognitive workloads while elevating quality…
CorFlow Therapeutics Secures FDA Approval for MOCA-II Pivotal Study of Innovative Heart Attack Treatment Technology
A pioneer in cardiac treatment for microvascular disease, today announced that the U.S. Food & Drug Administration (FDA) has granted its technology an Investigational Use Exemption (IDE), allowing the pivotal clinical trial to begin in U.S. hospitals. CorFlow will now…